An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
nContact Surgical, Inc. announced today the presentation of data collected from 43 patients as a result of a closed chest convergent atrial fibrillation (AF) procedure at the Heart Rhythm Society 2010 Conference in Denver, Colorado.
Medtronic, Inc. released the Virtual ICD study data today that predicted 98 percent of studied implantable defibrillator patients would be free of inappropriate shocks one year after implant and 92 percent at five years post-implant.
St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) clearance, CE Mark approval and the launch of the EnSite Derexi™ module, which provides improved electrophysiology (EP) lab efficiency and workflow by enabling communication between the EnSite™ Velocity™ Cardiac Mapping System and the EP-Workmate™ Recording System.
Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.
Cameron Health, Inc. today announced the publication of study results online in the New England Journal of Medicine highlighting the development and potential benefits of the company's S-ICD- System, the first minimally invasive, subcutaneous implantable cardioverter defibrillator, for the treatment of sudden cardiac arrest.
GE Healthcare, the healthcare business of GE and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.
Spectranetics Corporation today announced it will showcase a new advanced Laser Lead Extraction Simulation system at the Heart Rhythm Society's (HRS) 31st Annual Scientific Sessions, Heart Rhythm 2010. The new simulation system is intended to augment traditional procedural training for physicians on laser-assisted lead extraction procedures by permitting hands-on practice with extraction tools and techniques in multiple case scenarios in a virtual operating environment.
Stereotaxis, Inc. today announces the introduction of its new Vdrive™, an expansion of its Magnetic Navigation platform that facilitates remote manipulation of diagnostic devices used during electrophysiology (EP) procedures. The company is planning to preview the Vdrive at the HRS meeting this week, and will be commercially available when regulatory processes are complete.
St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) of its AnalyST™ implantable cardioverter defibrillator (ICD) with ST Monitoring, a revolutionary device that not only provides life-saving therapy for dangerously fast heart rhythms, but also continuously monitors electrical changes (called ST segments) to help physicians monitor for cardiac problems.
Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.
Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to the Company's LATITUDE® Patient Management system. The LATITUDE system enables physicians to remotely monitor patients with implantable cardiac devices. The upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data.
Medtronic, Inc. announced today that it now offers the new Medtronic M-Link™ cellular accessory, which provides cardiac device patients with an option to securely send information stored in their implanted devices to their clinics via the CareLink® Network using cellular signals, rather than a telephone landline. This simplified connection to the CareLink® Network enables clinicians to remotely monitor more patients who are implanted with cardiac devices.
LifeWatch Services, Inc., a subsidiary of LifeWatch AG, will unveil its advanced AF TeleClinic service offering this week at the Heart Rhythm Society (HRS) Annual Meeting taking place in Denver, Colorado. The AF TeleClinic service, empowered with the latest communication, IT and medical technologies, ensures physicians are well equipped to deliver optimal diagnostic and treatment options to their patients.
The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents
NewCardio, Inc., a cardiac diagnostic technology provider, will unveil its patented CardioBip technology for remote wireless 12-lead detection and monitoring of atrial fibrillation, ischemia and other cardiovascular events at the Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.
After a strong Q4 in 2009, net sales decreased 14% in Q1 to SEK 2,943 million (3,437). Mainly currency effects but also increased competition for Astelin and Optivar reduced sales by more than SEK 400 million, compared with the same period last year.
A pioneering world first robotics system operation is to be conducted at Glenfield Hospital Leicester thanks to expertise at the University of Leicester and University Hospitals of Leicester.
PulseOximetersDIRECT.com, the leading online retailer of portable Pulse Oximeter products introduces today the new FDA approved Landon Medical PC-60C2 Finger Pulse Oximeter for home use.
The strong growth within our Service Line Bariatrics continues, above all at our oldest clinic Bariatric Center Stockholm. Our arrhythmia clinic Arrhythmia Center Stockholm has also had good capacity utilization during the quarter and continues to generate better than expected results.
In a new study, researchers at Mount Sinai School of Medicine have taken a major step toward the ability to predict adverse drug reactions, using genetic, cellular, and clinical information to learn why some medicines cause heart arrhythmias in patients. Published in the April 20 issue of the journal Science Signaling, the new framework described in the study could potentially be applied to the study of medications that treat other diseases and disorders such as epilepsy and autism.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.